KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
Por:
Rugo, H, Llombart-Cussac, A, Andre, F, Robson, M, Saji, S, Harbeck, N, Schmid, P, Cescon, D, Ahn, J, Nanda, R, Fan, L, Mejia, J, Karantza, V and Bardia, A
Publicada:
1 feb 2021
Resumen:
Filiaciones:
Rugo, H:
Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
:
Hosp Arnau Vilanova, Valencia, Spain
Andre, F:
Gustave Roussy, Fac Med Paris Sud XI, Villejuif, France
Robson, M:
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
Saji, S:
Fukushima Med Univ, Fukushima, Japan
Harbeck, N:
Ludwig Maximilian Univ Munich LMU, Breast Ctr, Munich, Germany
Schmid, P:
Barts Canc Inst, London, England
Cescon, D:
Univ Toronto, Toronto, ON, Canada
Ahn, J:
Sungkyunkwan Univ, Coll Med, Seoul, South Korea
Nanda, R:
Univ Chicago, Chicago, IL 60637 USA
Fan, L:
Merck & Co Inc, Kenilworth, NJ USA
Mejia, J:
Merck & Co Inc, Kenilworth, NJ USA
Karantza, V:
Merck & Co Inc, Kenilworth, NJ USA
Bardia, A:
Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
|